摘要
目的探讨布地奈德福莫特罗联合二羟丙茶碱治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床效果及对患者肺功能、应激反应的影响。方法选取我院2016年4月至2017年8月收治的82例AECOPD患者,随机分为对照组和观察组各41例。对照组予以二羟丙茶碱治疗,观察组在此基础上采用布地奈德福莫特罗雾化吸入治疗。比较两组的临床疗效、治疗前后的肺功能与氧化应激指标。结果治疗1周后,观察组的总有效率明显高于对照组(P <0.05)。治疗后,两组的FEV_1、 FEV_1%pred、FEV1/FVC均明显上升,且观察组的FEV_1、 FEV_1%pred、 FEV_1/FVC均明显高于对照组(P均<0.05)。治疗后,两组的血清MDA水平显著下降, SOD水平显著升高,且观察组的血清MDA、 SOD水平均显著优于对照组(P均<0.05)。结论布地奈德福莫特罗联合二羟丙茶碱治疗AECOPD可迅速消除患者的症状体征,改善其肺功能,调控机体氧化应激状态,疗效显著。
Objective To explore the clinical effect of budesonide formoterol combined with diprophylline in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD) and the influence on the lung function and stress response of patients.Methods 82 cases of AECOPD patients admitted to our hospital from April 2016 to August 2017 were selected and randomly divided into control group and observation group, with 41 cases in each group. The control group was treated with diprophylline, while the observation group was treated with budesonide formoterol atomization inhalation on this basis. The clinical efficacy and the indicators of lung function and oxidative stress were compared between the two groups. Results 1 week after treatment, the total effective rate of the observation group was significantly higher than that of the control group(P<0.05). After treatment, the FEV1, FEV1% pred and FEV1/FVC of both groups increased significantly, and the FEV1, FEV1%pred and FEV1/FVC of the observation group were significantly higher than those of the control group(all P<0.05). After treatment, the serum MDA levels of both groups decreased significantly, the SOD levels increased significantly,and the serum MDA and SOD levels of the observation group were significantly better than those of the control group(all P<0.05).Conclusions Budesonide formoterol combined with diprophylline in the treatment of AECOPD can effectively eliminate patients’ symptoms and signs, improve the lung function and regulate the oxidative stress of organisms, with significant curative effect.
作者
平佳宜
肖文静
刘丰林
付海申
PING Jiayi;XIAO Wenjing;LIU Fenglin;FU Haishen(Kaifeng Hospital of Traditional Chinese Medivine, Kaifeng 475000,China)
出处
《临床医学工程》
2019年第3期365-366,共2页
Clinical Medicine & Engineering